Goodwin advised Blueprint Medicines on the deal. Blueprint Medicines announced its strategic collaboration with Proteovant Therapeutics that will leverage Proteovant Therapeutics’ artificial intelligence-enhanced targeted protein degradation platform […]
Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc. […]
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing […]
